capmatinib

a c-Met inhibitor

Also Known As:

2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzoic acid; 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)-(1,2,4)triazin-2-yl)benzamide; 2-fluoro-N-methyl-4-(7-(quinolin-6-yl-methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide; 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- b)(1,2,4)triazin-2-yl)benzamide dihydrochloride monohydrate; 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide dihydrochloride; CMC-583; CMC583; CNJ-294; CNJ294; INC-280; INC280; INCB-28060; INCB-28060 free base; INCB28060; NVP-INC280; NVP-INC280-NX; Tabrecta; capmatinib dihydrochloride; capmatinib dihydrochloride monohydrate; capmatinib hydrochloride; capmatinib hydrochloride anhydrous; capmatinib metabolite M13; capmatinib metabolite M18

Networked: 115 relevant articles (10 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zhao, Sylvia: 5 articles (12/2020 - 11/2018)
2.	Giovannini, Monica: 4 articles (01/2021 - 01/2020)
3.	Tiedt, Ralph: 4 articles (12/2020 - 01/2019)
4.	Cui, Xiaoming: 3 articles (01/2021 - 01/2020)
5.	Heist, Rebecca S: 3 articles (01/2021 - 01/2020)
6.	Tan, Daniel S W: 3 articles (01/2021 - 11/2018)
7.	Hao, Huai-Xiang: 3 articles (12/2020 - 12/2018)
8.	Akimov, Mikhail: 3 articles (02/2020 - 11/2018)
9.	Abd El-Aty, A M: 2 articles (04/2022 - 01/2021)
10.	Jeong, Ji Hoon: 2 articles (04/2022 - 01/2021)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2020 - "Capmatinib may be effective in patients with advanced non-small cell lung cancer who have MET exon 14 skipping mutations. " 01/01/2023 - "Capmatinib, a MET inhibitor, showed substantial antitumour activity with manageable side effects in patients with MET exon 14 (METex14)-mutated advanced non-small cell lung cancer (aNSCLC) in the GEOMETRY mono-1 study. " 04/01/2021 - "Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies." 01/01/2021 - "In the Phase II GEOMETRY mono-1 study, the potent and selective mesenchymal-epithelial transition (MET) inhibitor capmatinib exhibited considerable efficacy in MET exon 14 skipping (METex14)-mutated metastatic non-small cell lung cancer at a dose of 400 mg BID. " 11/16/2023 - "MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer."
2.	Neoplasms (Cancer) 01/01/2020 - "Besides, capmatinib effectively improved the in vivo anticancer efficacy of both CIS and DOX against solid tumors. " 03/01/2020 - "Aim: Capmatinib is an orally bioavailable mesenchymal-epithelial transition factor inhibitor with anticancer activity, which has proved preclinical activity in multiple cancer trials. " 02/01/2020 - "Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts." 11/16/2023 - "In vivo, the combination of capmatinib and radiation significantly delayed tumor growth compared to vehicle control, capmatinib alone, or radiation alone. " 10/27/2023 - "In vivo, the combination of capmatinib and radiation significantly delayed tumor growth compared to vehicle control, capmatinib alone, or radiation alone. "
3.	Neoplasm Metastasis (Metastasis) 01/01/2022 - "Our report highlights the significant CNS activity of capmatinib, even in cases of leptomeningeal metastasis. " 01/01/2016 - "Our data demonstrate for the first time a role for pre-OBs in mediating HGF/MET- dependent migration of BC cells and strongly support the clinical evaluation of INCB28060 and other MET inhibitors to limit and/or prevent BC-associated bone metastases." 07/03/2015 - "The objective of this study was to determine the efficacy of a novel, highly potent, orally-bioavailable c-MET inhibitor, INC280, in blocking cell phenotypes important in ovarian cancer metastasis. " 01/01/2022 - "Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis." 07/03/2015 - "Overall, these data indicate that INC280 inhibits many cell behaviours that promote ovarian cancer metastasis, and merits further investigation as a therapeutic candidate in the treatment of patients with ovarian cancer. "
4.	Ovarian Neoplasms (Ovarian Cancer) 07/03/2015 - "INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models." 07/03/2015 - "The objective of this study was to determine the efficacy of a novel, highly potent, orally-bioavailable c-MET inhibitor, INC280, in blocking cell phenotypes important in ovarian cancer metastasis. " 07/03/2015 - "Overall, these data indicate that INC280 inhibits many cell behaviours that promote ovarian cancer metastasis, and merits further investigation as a therapeutic candidate in the treatment of patients with ovarian cancer. " 01/01/2017 - "Ovarian cancer cell line SKOV3 and OVCAR-3 were pretreated with c-Met inhibitor INCB28060, and then treated with paclitaxel. " 01/01/2017 - "Western blotting analysis also showed that CAF-derived HGF or recombinant HGF activated c-Met/phosphoinositide 3-kinase (PI3K)/Akt and glucose-regulated protein 78 (GRP78) signalling pathways in ovarian cancer cells, and these effects could be abrogated by anti-HGF and c-Met inhibitor INCB28060. "
5.	Disease Progression 01/01/2023 - "After the DDI phase, patients received capmatinib on continuous 21-day cycles until disease progression at the discretion of the investigator. " 11/01/2018 - "This phase Ib/II study investigated the safety and efficacy of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated (amplified/overexpressing) NSCLC who experienced disease progression while receiving EGFR-TKI treatment. "

Related Drugs and Biologics

1.	tepotinib
2.	Gefitinib (Iressa)
3.	osimertinib
4.	Erlotinib Hydrochloride (CP 358,774)
5.	Phosphotransferases (Kinase)
6.	Gemcitabine
7.	merestinib
8.	pitavastatin (itavastatin)
9.	capmatinib
10.	Tyrosine Kinase Inhibitors

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Salvage Therapy
4.	Intravenous Injections
5.	Oral Administration